Vertex Pharmaceuticals Inc VRTX

NASDAQ US Health Care Biotechnology

$526.73 ▼ -0.18% ($-0.94)

Index member: S&P 500

Open $522.22

Prev Close $527.67

Day Range $519.25 – $529.46

52W Range $379.72 – $560.25

Market Cap $121.09B

P/E (TTM) 30.21

Beta 0.28

EPS (TTM) $17.19

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-07-24
Shares Out.	253,810,000
Website	vrtx.com/ ↗
Phone	16173416393
Employees	6,400
Revenue	$3.33B
Gross Profit	$2.84B
Net Income	$1.10B
Free Cash Flow	$3.80B
Total Assets	$27.42B
Total Liabilities	$7.18B
Equity	$20.25B

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Vertex Pharmaceuticals Inc is a publicly traded company under the ticker symbol VRTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.